The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections - Yahoo Finance

The Lancet Infectious Diseases Publishes Results from Paratek’s Phase 3 Oral only Dosing Study of NUZYRA® (omadacycline) for Skin Infections  Yahoo Finance

Once-daily NUZYRA is non-inferior to twice-daily oral linezolid for the treatment of adults with ABSSSI, including MRSA; confirms efficacy and safety of oral-only ...



Comments

Popular posts from this blog

Common Questions About Vaccines (for Parents) | Nemours KidsHealth

GROWING PROBLEM Botched penis enlargement epidemic hits Papua New Guinea as docs warn 500 have injected todgers with coconut oil - Information-Analytic Agency NEWS.am